货号（Catalog No.）icon

CSD00086

通用名INNicon

Lumiliximab

纯度(Purity)icon

>95%

浓度( Concentration)icon

1mg/ml

Formulationicon

PBS buffer pH7.5

Sourceicon

CHO cells

内毒素(Endotoxin level)icon

Please contact with the lab for this information.

生物活性icon

产品描述(Description)

Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody,for the potential treatment of allergic conditions.Lumiliximab was developed by IDEC Pharmaceuticals,which was acquired by Biogen.Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.Lumiliximab is a chimeric macaque-human monoclonal antibody to CD23,a protein expressed on virtually all chronic lymphocytic leukemia (CLL) cells.CD23, also known as Fc epsilon RII,or FcεRII,is the "low affinity" receptor for IgE, an antibody isotype involved in allergy and resistance to parasites and is important in regulation of IgE levels. Unlike many of the antibody receptors, CD23 is a C-type lectin. It is found on mature B cells,activated macrophages, eosinophils, follicular dendritic cells and platelets.

别名(Alternative names)

IDEC-152,P5E8

靶点;物种(Specificity target name;species)

FCER2[Homo sapiens]

种类(Species)

Chimeric

受体鉴定(Receptor identification)

IgG1-kappa

化学信息icon

分子量(MV)

47750.00 Da

CAS

357613-86-6

存储条件(Storage)

store at -80°C